Akari Therapeutics (AKTX) Net Cash Flow Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 32.17% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.44% |
| Jun 30, 2025 | 26.30% |
| Mar 31, 2025 | -26.04% |
| Dec 31, 2024 | -99.64% |
| Sep 30, 2024 | 98.57% |
| Jun 30, 2024 | 37.32% |
| Mar 31, 2024 | 30.13% |
| Dec 31, 2023 | 99.48% |
| Sep 30, 2023 | -25.99% |
| Jun 30, 2023 | 98.73% |
| Mar 31, 2023 | -25.99% |
| Jun 30, 2022 | -35.37% |
| Mar 31, 2022 | 166.47% |
| Dec 31, 2021 | 5,301.32% |
| Sep 30, 2021 | -5,013.10% |
| Jun 30, 2021 | 16.25% |
| Mar 31, 2021 | -19.04% |
| Dec 31, 2020 | -8,974.29% |
| Sep 30, 2020 | 8,739.52% |
| Jun 30, 2020 | -7,292.97% |
| Mar 31, 2020 | 6,054.21% |
| Dec 31, 2019 | -26.50% |
| Sep 30, 2019 | 42.21% |
| Jun 30, 2019 | 59.44% |
| Mar 31, 2019 | 27.07% |
| Dec 31, 2018 | 24.56% |
| Sep 30, 2018 | -27.31% |
| Jun 30, 2018 | -90.08% |
| Mar 31, 2018 | -30.29% |
| Dec 31, 2017 | -66.80% |
| Sep 30, 2017 | -30.27% |
| Jun 30, 2017 | 60.60% |
| Mar 31, 2017 | -51.64% |